🔗

Mappings

MONDO

MONDO:0010922 Satoyoshi syndrome

Primary MONDO disease term for this entry.

📘

Definitions

1

Literature case definition for Satoyoshi syndrome

Case-level definition synthesized from systematic reviews, centered on the characteristic triad with multisystem supportive features and autoimmune context.

CASE_DEFINITION Published case reports and case series

Core clinical triad

Characteristic high-yield symptom cluster for case recognition.

Minimum required: 2

Core clinical characteristics

Intermittent painful muscle spasms
Alopecia
Chronic diarrhea

Multisystem supportive manifestations

Frequent associated findings that strengthen diagnostic confidence.

Minimum required: 1

Inclusion criteria

Malabsorption
Secondary amenorrhea
Abnormality of the skeletal system

Exclusion criteria

Alternative causes of painful muscle spasms and chronic diarrhea excluded

Show evidence (3 references)

PMID:31217029 SUPPORT Human Clinical

"Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities."

This supports the core triad-plus-skeletal pattern used for case definition.

PMID:36749015 SUPPORT Human Clinical

"All cases had painful muscular spasms and alopecia."

Universal occurrence of spasms and alopecia supports high-weight core criteria.

PMID:36749015 SUPPORT Human Clinical

"Frequent manifestations included: diarrhoea, malabsorption, growth retardation, amenorrhoea and bone deformity."

This supports inclusion of multisystem supportive criteria.

⚙

Pathophysiology

6

Systemic Autoimmune Activation

Satoyoshi syndrome shows systemic immune activation with circulating ANA and other autoantibodies in a substantial subset of cases.

Lymphocyte link Plasma Cell link

B Cell Mediated Immunity link Adaptive Immune Response link

Show evidence (3 references)

PMID:32429959 SUPPORT Human Clinical

"Antinuclear antibodies were detected in 8 out of 16 cases. Antibodies to stomach or duodenum tissue lysates were also detected by Western blot."

Detection of ANA and additional tissue-reactive antibodies supports systemic autoimmunity as an upstream disease event.

PMID:36749015 SUPPORT Human Clinical

"Autoantibody determinations were performed in 39 patients, of which 27 had positive results. The most frequently detected autoantibodies were ANAs."

This broader systematic review confirms frequent autoantibody positivity and ANA predominance, reinforcing systemic autoimmune activation.

PMID:28940615 SUPPORT Human Clinical

"It is a rare multisystem disorder of presumed autoimmune etiology that is characterized by alopecia, intermittent painful muscle spasms, diarrhea, and antinuclear antibody positivity."

Independent case-report abstract supports autoimmune etiology and ANA positivity in Satoyoshi syndrome.

Tissue-Reactive Autoantibody Production

Western blot studies identified circulating antibodies that react with brain, stomach, and duodenal tissue lysates, consistent with a shared tissue-targeted autoimmune response.

Show evidence (2 references)

PMID:17405137 SUPPORT Human Clinical

"A common antibody against brain, stomach, and duodenal tissue, according to Western blot analysis, was detected in the sera of two patients with this syndrome. These findings suggest that Satoyoshi syndrome is a systemic autoimmune disease involving the nervous, endocrine, and gastrointestinal systems."

This report directly demonstrates tissue-reactive antibodies spanning nervous and gastrointestinal systems.

PMID:32429959 SUPPORT Human Clinical

"Antibodies to stomach or duodenum tissue lysates were also detected by Western blot."

Independent systematic-review evidence reproduces gastrointestinal tissue-reactive antibody detection.

Neuromuscular Circuit Dysfunction

Immune-mediated dysfunction of motor circuitry and neuromuscular signaling is a plausible proximal mechanism for abnormal muscle activation.

Skeletal Muscle Fiber link

Regulation of Muscle Contraction link Neuromuscular Transmission link

Show evidence (4 references)

PMID:31217029 SUPPORT Human Clinical

"Satoyoshi syndrome is a multisystemic rare disease of unknown etiology, although an autoimmune basis is presumed. Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities."

Systematic review of 64 cases confirms painful muscle spasms as a universal feature, with autoimmune basis presumed but specific neuromuscular mechanism not yet resolved.

PMID:16972238 SUPPORT Human Clinical

"These findings point to hyperactivity or a disinhibition at the alpha motor neuron level, originating probably at that level, although a central origin cannot be excluded."

Electrophysiologic data support alpha motor neuron hyperexcitability as a proximal mechanism for painful involuntary contractions.

PMID:16972238 SUPPORT Human Clinical

"During the involuntary contractions, HD-sEMG showed a fourfold increase in amplitude compared to maximal voluntary contractions."

Objective EMG amplitude amplification supports abnormal neuromuscular circuit excitability as a proximal event.

+ 1 more reference

Gastrointestinal Mucosal Inflammation

Histology shows predominantly lymphoplasmacytic inflammatory infiltrates across the digestive tract.

Lymphocyte link Plasma Cell link

Inflammatory Response link

Show evidence (2 references)

PMID:32429959 SUPPORT Human Clinical

"Histological data revealed predominantly lymphoplasmacytic inflammatory infiltrate that can affect any section of the digestive tract."

Histological evidence confirms inflammatory infiltration of the GI tract consistent with autoimmune-mediated enteropathy.

PMID:17405137 SUPPORT Human Clinical

"We present a patient with this syndrome having a unique "mesh-like" mucosal change radiographically and white granules endoscopically in the gastrointestinal tract."

Independent endoscopic/radiographic mucosal abnormalities further support GI tissue pathology in Satoyoshi syndrome.

Intestinal Absorptive Dysfunction

Carbohydrate malabsorption is demonstrated by abnormal D-xylose and oral glucose tolerance testing.

Intestinal Absorption link ↓ DECREASED

Show evidence (3 references)

PMID:32429959 SUPPORT Human Clinical

"Chronic diarrhea was the main digestive symptom (92.3%). Other symptoms such as abdominal pain (15.4%), nausea (7.7%) and vomiting (7.7%), were less frequent. The D-xylose test was positive in 10 out of 12 patients, and 9 out of 13 cases showed a flattened oral glucose tolerance test suggesting..."

Clinical testing demonstrates carbohydrate malabsorption and its close association with chronic diarrhea.

PMID:32429959 SUPPORT Human Clinical

"Chronic diarrhea may be severe and result in malnutrition, anemia, growth retardation, cachexia, disability and even death."

This links prolonged gastrointestinal dysfunction to downstream growth consequences.

PMID:32429959 SUPPORT Human Clinical

"Chronic diarrhea with malabsorption is one of the most disabling symptoms in SS."

This conclusion-level statement directly supports clinically significant absorptive dysfunction.

Hair Follicle Immune Injury

Autoimmune targeting of follicular units is a plausible mechanism for the characteristic diffuse hair loss phenotype.

Immune Response link

Show evidence (2 references)

PMID:31217029 SUPPORT Human Clinical

"Satoyoshi syndrome is a multisystemic rare disease of unknown etiology, although an autoimmune basis is presumed. Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities."

Systematic review confirms alopecia as one of the main symptoms present in 100% of reported cases.

PMID:36749015 SUPPORT Human Clinical

"All cases had painful muscular spasms and alopecia."

The larger 77-case review confirms alopecia as a universal feature, supporting an upstream follicular injury mechanism.

✶

Histopathology

2

Gastrointestinal lymphoplasmacytic inflammatory infiltrate FREQUENT

Digestive tract histology shows predominantly lymphoplasmacytic inflammatory infiltrates, consistent with inflammatory enteropathy.

Show evidence (1 reference)

PMID:32429959 SUPPORT Human Clinical

"Histological data revealed predominantly lymphoplasmacytic inflammatory infiltrate that can affect any section of the digestive tract."

This directly supports a characteristic microscopic inflammatory finding in Satoyoshi syndrome gastrointestinal disease.

Gastrointestinal mucosal structural abnormalities OCCASIONAL

Reported gastrointestinal pathology includes diffuse mucosal structural abnormalities seen on radiographic and endoscopic assessment.

Show evidence (1 reference)

PMID:17405137 SUPPORT Human Clinical

"We present a patient with this syndrome having a unique "mesh-like" mucosal change radiographically and white granules endoscopically in the gastrointestinal tract."

This supports additional gastrointestinal tissue-level pathology beyond the inflammatory infiltrate pattern.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

10

Digestive 2

Chronic Diarrhea VERY_FREQUENT Chronic diarrhea (HP:0002028)

Present in 92.3% of cases with GI involvement; can be fatal

Show evidence (3 references)

PMID:32429959 SUPPORT Human Clinical

"Chronic diarrhea was the main digestive symptom (92.3%)."

Systematic review identifies chronic diarrhea as the predominant GI symptom in 92.3% of cases with gastrointestinal manifestations.

PMID:36749015 SUPPORT Human Clinical

"Frequent manifestations included: diarrhoea, malabsorption, growth retardation, amenorrhoea and bone deformity."

Broader case synthesis also classifies diarrhoea as a frequent Satoyoshi manifestation.

PMID:28267828 SUPPORT Human Clinical

"Thereafter, she developed chronic diarrhea, amenorrhea, and skeletal deformities."

Case history report independently documents chronic diarrhea among multisystem Satoyoshi manifestations.

Malabsorption VERY_FREQUENT Malabsorption (HP:0002024)

D-xylose and oral glucose tolerance tests demonstrate carbohydrate malabsorption

Show evidence (2 references)

PMID:32429959 SUPPORT Human Clinical

"The D-xylose test was positive in 10 out of 12 patients, and 9 out of 13 cases showed a flattened oral glucose tolerance test suggesting carbohydrate malabsorption."

Objective malabsorption testing demonstrates carbohydrate malabsorption in the majority of tested patients.

PMID:36749015 SUPPORT Human Clinical

"Frequent manifestations included: diarrhoea, malabsorption, growth retardation, amenorrhoea and bone deformity."

Independent systematic review evidence confirms malabsorption as a frequent manifestation.

Eye 1

Uveitis VERY_RARE Uveitis (HP:0000554)

Newly reported complication (2023); granulomatous pan-uveitis with impending CRVO

Show evidence (1 reference)

PMID:36930111 SUPPORT Human Clinical

"Unilateral granulomatous pan-uveitis and impending CRVO were observed in this patient. Several cases of Satoyoshi syndrome complicated by various autoimmune or immunological disorders have been reported. However, to the best of our knowledge, no reports of Satoyoshi syndrome presenting with..."

First reported case of uveitis in Satoyoshi syndrome, expanding the known organ spectrum of the disease and supporting systemic autoimmune pathogenesis.

Genitourinary 1

Amenorrhea VERY_FREQUENT Secondary amenorrhea (HP:0000869)

Secondary amenorrhea in affected females

Show evidence (3 references)

PMID:36749015 SUPPORT Human Clinical

"Frequent manifestations included: diarrhoea, malabsorption, growth retardation, amenorrhoea and bone deformity."

Systematic review of 77 cases identifies amenorrhoea as one of the frequent manifestations of Satoyoshi syndrome.

PMID:15069249 SUPPORT Human Clinical

"Satoyoshi syndrome (Komuragaeri disease) is a rare disorder of presumed autoimmune etiology, characterized by painful muscle spasms, alopecia, diarrhea, endocrinopathy with amenorrhoea and secondary skeletal abnormalities."

Independent case report abstract explicitly includes amenorrhoea in the characteristic syndrome phenotype.

PMID:28267828 SUPPORT Human Clinical

"Thereafter, she developed chronic diarrhea, amenorrhea, and skeletal deformities."

Additional case evidence directly supports amenorrhea in Satoyoshi syndrome.

Integument 2

Alopecia OBLIGATE Alopecia (HP:0001596)

Alopecia reported in 100% of cases across systematic reviews

Show evidence (2 references)

PMID:36749015 SUPPORT Human Clinical

"All cases had painful muscular spasms and alopecia."

The largest systematic review (77 cases) reports alopecia as universal in Satoyoshi syndrome.

PMID:31217029 SUPPORT Human Clinical

"Satoyoshi syndrome is a multisystemic rare disease of unknown etiology, although an autoimmune basis is presumed. Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities."

Independent systematic review (64 cases) also identifies alopecia as a core syndrome feature.

Alopecia Universalis FREQUENT Alopecia universalis (HP:0002289)

Universalis subtype reported in approximately 63% of cases

Show evidence (2 references)

PMID:36930111 SUPPORT Human Clinical

"At the age of 7 years, she developed generalized hair loss and painful spasms and was diagnosed with Satoyoshi syndrome."

Case report documents generalized hair loss as a presenting feature of Satoyoshi syndrome.

PMID:28940615 SUPPORT Human Clinical

"We report an 11-year-old girl with Satoyoshi syndrome who presented to the dermatology department for treatment of alopecia universalis."

Case report directly documents alopecia universalis as a presenting phenotype.

Musculoskeletal 2

Painful Muscle Spasms OBLIGATE Intermittent painful muscle spasms (HP:0011964)

Progressive, painful intermittent spasms (komuragaeri) especially of limbs and trunk; present in 100% of cases

Show evidence (3 references)

PMID:31217029 SUPPORT Human Clinical

"Satoyoshi syndrome is a multisystemic rare disease of unknown etiology, although an autoimmune basis is presumed. Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities."

Painful muscle spasms are listed as one of the cardinal symptoms in this systematic review of 64 cases.

PMID:36749015 SUPPORT Human Clinical

"All cases had painful muscular spasms and alopecia."

Independent 77-case review confirms painful spasms as a universal phenotype.

PMID:9804090 SUPPORT Human Clinical

"Satoyoshi syndrome consists of painful intermittent muscle spasms, alopecia and diarrhea."

Adult-onset review independently confirms painful intermittent spasms as a core phenotype.

Skeletal Abnormalities FREQUENT Abnormality of the skeletal system (HP:0000924)

Skeletal alterations reported in approximately 34% of cases

Show evidence (4 references)

PMID:31217029 SUPPORT Human Clinical

"Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities."

Skeletal abnormalities are listed as one of the main symptoms in this systematic review of 64 cases.

PMID:15069249 SUPPORT Human Clinical

"Satoyoshi syndrome (Komuragaeri disease) is a rare disorder of presumed autoimmune etiology, characterized by painful muscle spasms, alopecia, diarrhea, endocrinopathy with amenorrhoea and secondary skeletal abnormalities."

Independent case literature explicitly reports secondary skeletal abnormalities as part of the syndrome.

PMID:28267828 SUPPORT Human Clinical

"Thereafter, she developed chronic diarrhea, amenorrhea, and skeletal deformities."

Independent case evidence supports skeletal deformities as part of the phenotype spectrum.

+ 1 more reference

Constitutional 1

Abdominal Pain OCCASIONAL Abdominal pain (HP:0002027)

Show evidence (1 reference)

PMID:32429959 SUPPORT Human Clinical

"Other symptoms such as abdominal pain (15.4%), nausea (7.7%) and vomiting (7.7%), were less frequent."

Abdominal pain reported in 15.4% of cases with gastrointestinal involvement.

Growth 1

Short Stature FREQUENT Short stature (HP:0004322)

Common in pediatric cases, plausibly secondary to malabsorption and chronic inflammation

Show evidence (2 references)

PMID:32429959 SUPPORT Human Clinical

"Chronic diarrhea may be severe and result in malnutrition, anemia, growth retardation, cachexia, disability and even death."

Growth retardation is listed as a consequence of severe chronic diarrhea and malabsorption in Satoyoshi syndrome.

PMID:36749015 SUPPORT Human Clinical

"Frequent manifestations included: diarrhoea, malabsorption, growth retardation, amenorrhoea and bone deformity."

Systematic review independently confirms growth retardation as a frequent manifestation.

🧬

Genetic Associations

1

No established monogenic etiology (Unknown)

Show evidence (2 references)

PMID:31217029 SUPPORT Human Clinical

"Satoyoshi syndrome is a multisystemic rare disease of unknown etiology, although an autoimmune basis is presumed."

This review explicitly states that disease etiology remains unknown.

PMID:16972238 SUPPORT Human Clinical

"Although an autoimmune origin of Satoyoshi syndrome seems likely, its exact etiology remains as yet unknown, as is the origin of the involuntary contractions."

Electrophysiology-focused case study confirms unresolved etiology despite autoimmune evidence.

💊

Treatments

4

Corticosteroids

Action: corticosteroid agent therapy MAXO:0000640

First-line treatment with the best overall results. 28 out of 30 cases responded to a regimen that included corticosteroids. Corticosteroid-containing regimens improved diarrhea in 6 out of 10 patients with GI involvement. None of the three patients who died had received corticosteroids or immunosuppressants.

Show evidence (3 references)

PMID:31217029 SUPPORT Human Clinical

"28 out of 30 cases responded to a regimen that included costicosteroids."

Systematic review demonstrates that corticosteroid-containing regimens produced favorable responses in the large majority of treated cases.

PMID:32429959 SUPPORT Human Clinical

"In 6 out of 10 patients, diarrhea improved with a treatment regimen that included corticosteroids."

Corticosteroid-containing regimens specifically improved gastrointestinal symptoms, supporting the inflammatory/autoimmune basis of the enteropathy.

PMID:32429959 SUPPORT Human Clinical

"None of the three patients who died had received corticosteroids or immunosuppressants."

The observation that all fatal cases lacked immunosuppressive treatment suggests corticosteroids may reduce mortality, though publication bias must be considered.

Dantrolene

Action: skeletal muscle relaxant agent therapy MAXO:0000324

Muscle relaxant that improved muscle symptoms in 13 out of 15 cases, but did not improve any other symptoms of the disease. Used for symptomatic management of painful spasms.

Show evidence (1 reference)

PMID:31217029 SUPPORT Human Clinical

"Dantrolene improved muscle symptoms in 13 out of 15 cases, but not any other symptoms of the disease."

Dantrolene is effective for muscle spasm control but does not address the underlying autoimmune process or other systemic manifestations.

Immunosuppressive Agents

Action: pharmacotherapy MAXO:0000058

Various immunosuppressants including cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus, and cyclophosphamide have been used as steroid-sparing agents or to improve efficacy of treatment.

Show evidence (1 reference)

PMID:31217029 SUPPORT Human Clinical

"Other immunosuppressive drugs including cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, tacrolimus and cyclophosphamide were used to decrease corticosteroid dose or improve efficacy."

Multiple immunosuppressive agents have been employed as steroid-sparing therapy in Satoyoshi syndrome.

Intravenous Immunoglobulin (IVIG)

Action: pharmacotherapy MAXO:0000058

Used in some cases with variable response. Four out of nine patients treated with IVIG obtained a favorable response.

Show evidence (1 reference)

PMID:31217029 PARTIAL Human Clinical

"Immunoglobulin therapy was used in nine patients and four of them obtained a favorable response."

IVIG produced favorable responses in less than half of treated patients, indicating variable efficacy.

🔬

Biochemical Markers

2

Antinuclear Antibodies (ANA) (Variable)

Context: Most commonly detected autoantibody; found in 8/16 GI-series cases and 21/39 in autoimmunity review

Show evidence (1 reference)

PMID:32429959 SUPPORT Human Clinical

"Antinuclear antibodies were detected in 8 out of 16 cases."

ANA are the most frequently detected autoantibody in Satoyoshi syndrome patients.

Anti-Brain and GI Tissue Antibodies (Positive)

Context: Circulating antibodies targeting a ~90 kDa antigen in brain, stomach, and duodenal lysates

Show evidence (1 reference)

PMID:17405137 SUPPORT Human Clinical

"A common antibody against brain, stomach, and duodenal tissue, according to Western blot analysis, was detected in the sera of two patients with this syndrome."

Western blot demonstrates a shared tissue-reactive autoantibody in Satoyoshi syndrome sera, supporting a common autoantigen across nervous and gastrointestinal systems.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from Satoyoshi Syndrome:

Classic stiff person syndrome Not Yet Curated MONDO:0018625

Overlapping Features Both disorders can present with painful muscle spasms, but classic stiff person syndrome is defined by prominent persistent body stiffness and characteristic axial involvement.

Distinguishing Features

Typical SPS presentation includes generalized body stiffness and exaggerated lumbar lordosis.
Satoyoshi syndrome instead has obligate alopecia and frequent chronic diarrhea/malabsorption.

Show evidence (3 references)

PMID:23186907 SUPPORT Human Clinical

"It is uncommon, characterized by body stiffness associated with painful muscle spasms, and varies in location and severity."

Confirms the painful spasm overlap and defining stiffness phenotype of SPS.

PMID:23186907 SUPPORT Human Clinical

"Most patients demonstrate exaggerated lumbar lordosis."

Lumbar lordosis is a characteristic SPS feature that helps distinguish it from Satoyoshi syndrome.

PMID:31217029 SUPPORT Human Clinical

"Its main symptoms are: painful muscle spasms, diarrhea, alopecia and skeletal abnormalities."

Satoyoshi-specific multisystem features (especially alopecia and diarrhea) help distinguish it from SPS.

Isaac syndrome Not Yet Curated MONDO:0019399

Overlapping Features Both disorders can involve painful cramps/spasms, but Isaac syndrome is a peripheral nerve hyperexcitability disorder with continuous motor activity and characteristic myokymia/fasciculations.

Distinguishing Features

Continuous motor activity with fasciculations and myokymia suggests Isaac syndrome.
Electrodiagnostic after-discharges and neuromyotonic/myokymic discharges are typical for Isaac syndrome.

Show evidence (2 references)

PMID:25736532 SUPPORT Human Clinical

"Isaacs syndrome is a peripheral nerve hyperexcitability (PNH) syndrome that presents as continuous motor activity. Clinical findings include cramps, fasciculations, and myokymia."

This defines key clinical features that separate Isaac syndrome from the broader multisystem Satoyoshi phenotype.

PMID:25736532 SUPPORT Human Clinical

"Electrodiagnosis plays a key role in diagnosis by demonstrating after-discharges on nerve conduction studies, and fasciculation potentials, myokymic discharges, neuromyotonic discharges, and other types of abnormal spontaneous activity on needle examination."

Characteristic electrodiagnostic findings provide a key differentiator from Satoyoshi syndrome.

📚

Literature Summaries

1

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 24 citations 2026-02-23T16:55:56.336159

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Satoyoshi Syndrome
MONDO ID: (if available)
Category: Autoimmune

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Satoyoshi Syndrome. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Title: Pathophysiology of Satoyoshi Syndrome (Komuragaeri disease): autoimmune multisystem disorder with neuromuscular hyperexcitability, alopecia, and inflammatory enteropathy

Publication context and evidence base Satoyoshi syndrome (SS) is a very rare multisystem disorder classically defined by the clinical triad of intermittent painful muscle spasms, alopecia (often progressing to alopecia universalis), and chronic diarrhea/malabsorption, with frequent skeletal and endocrine sequelae and a strong but not yet molecularly resolved autoimmune hypothesis. (pozo2019treatmentofsatoyoshi pages 2-4, pozo2019treatmentofsatoyoshi pages 1-2)

MONDO ID A MONDO identifier was not available from Open Targets lookup using the provided tools (no match returned). (no citable ID; tool error)

Key concepts and definitions (current understanding)

1.1 Definition and core clinical syndrome Systematic syntheses of reported cases define SS as a rare disorder with universal painful muscle spasms and alopecia, and frequent gastrointestinal involvement (commonly diarrhea/malabsorption) and skeletal abnormalities. (pozo2019treatmentofsatoyoshi pages 2-4, pozo2020gastrointestinalmanifestationsin pages 1-2, montanaro2022autoimmunityinsatoyoshi pages 1-5)

1.2 Current pathophysiologic concept: probable autoimmune multisystem disease Multiple independent lines of evidence support an autoimmune basis: (i) frequent autoantibodies (ANA and other specificities), (ii) inflammatory infiltrates in affected tissues (skin/hair follicles, GI mucosa; sometimes muscle), (iii) association with other autoimmune diseases in some patients, and (iv) high rates of clinical improvement with systemic immunomodulatory therapy (especially corticosteroids). (montanaro2022autoimmunityinsatoyoshi pages 1-5, montanaro2022autoimmunityinsatoyoshi pages 8-11, pozo2020gastrointestinalmanifestationsin pages 1-2, pozo2019treatmentofsatoyoshi pages 1-2)

Authoritative expert statements explicitly frame SS as autoimmune/probably autoimmune, for example: • 2007 primary report: “The dramatic effect of immunotherapy with glucocorticoids, … intravenous immunoglobulins, and tacrolimus … suggests that Satoyoshi syndrome is an autoimmune disease.” (matsuura2007satoyoshisyndromehas pages 1-2) • 2023 peer-reviewed case report: “The effectiveness of systemic corticosteroids and immunosuppressive drugs… as well as the typical presence of antinuclear antibodies… and autoantibodies against brain and intestinal organs… suggests the possibility of an autoimmune origin.” (saima2023impendingcentralretinal pages 4-5)

1.3 Central knowledge gap Despite the autoimmune evidence, a definitive causal autoantigen and causal gene(s) have not been established in the accessible literature; antibody reactivity is reported but antigen identity remains unknown. (matsuura2007satoyoshisyndromehas pages 2-4, montanaro2022autoimmunityinsatoyoshi pages 8-11)

Core pathophysiology: molecular pathways, cellular processes, and tissues

2.1 Immune-mediated tissue injury and inflammation (skin/hair follicles and gut) Across compiled cases, biopsies of skin/hair and gastrointestinal tract commonly show lymphocytic or lymphoplasmacytic inflammatory infiltrates, supporting an immune-mediated process affecting hair follicles and intestinal mucosa. (montanaro2022autoimmunityinsatoyoshi pages 8-11, pozo2020gastrointestinalmanifestationsin pages 1-2) In the GI-focused systematic review, histology is summarized as “predominantly lymphoplasmacytic inflammatory infiltrate” and is described as able to involve any segment of the digestive tract. (pozo2020gastrointestinalmanifestationsin pages 1-2) Cropped sections of the per-patient GI Table 1 (showing malabsorption testing and histology columns) visually corroborate that inflammatory histology and malabsorption testing recur across cases. (pozo2020gastrointestinalmanifestationsin media c2682e6c, pozo2020gastrointestinalmanifestationsin media 8c8b7812, pozo2020gastrointestinalmanifestationsin media cce4c213, pozo2020gastrointestinalmanifestationsin media da01f15f)

2.2 Autoantibody-associated mechanisms and candidate antigen classes 2.2.1 Tissue-reactive antibodies against brain and GI tissue (unknown 90 kDa antigen) A key primary mechanistic observation is Western blot evidence of patient serum binding a ~90 kDa band in brain, stomach, and duodenum lysates (with no band in control sera), implying a shared antigen expressed in nervous system and GI tissues. (matsuura2007satoyoshisyndromehas pages 2-4) This supports a model in which a circulating autoantibody response targets a widely expressed antigen relevant to neuromuscular symptoms and enteropathy; however, the antigen remains unidentified. (matsuura2007satoyoshisyndromehas pages 2-4)

2.2.2 Frequently reported autoantibodies (immune dysregulation signature) A systematic review of 77 cases reported that among 39 patients tested for autoantibodies, 27 (69.2%) had at least one autoantibody, most commonly ANA (21 patients). Other reported antibodies include anti-acetylcholine receptor (AChR), anti-DNA, antithyroid antibodies, anti-glutamic acid decarboxylase (GAD), and antigliadin. (montanaro2022autoimmunityinsatoyoshi pages 8-11, montanaro2022autoimmunityinsatoyoshi pages 1-5) In the GI systematic review, ANA were detected in 8/16 and antibodies to stomach/duodenal tissue lysates were reported by Western blot in some cases. (pozo2020gastrointestinalmanifestationsin pages 1-2)

Interpretation: these serologies are consistent with loss of immune tolerance and systemic autoimmunity, but they are not disease-specific biomarkers at present. (montanaro2022autoimmunityinsatoyoshi pages 8-11, pozo2020gastrointestinalmanifestationsin pages 1-2)

2.3 Neuromuscular hyperexcitability / dysregulated motor control In compiled reports, electrophysiological studies have been interpreted as suggesting dysregulation at the alpha motor neuron level, consistent with the severe, painful spasms that dominate the clinical phenotype. (montanaro2022autoimmunityinsatoyoshi pages 5-8) Mechanistically, this could reflect immune-mediated dysfunction of motor circuits or neuromuscular junction-related targets in a subset of patients (supported indirectly by anti-AChR antibodies reported in some cases), but specific targets and pathways remain unconfirmed. (montanaro2022autoimmunityinsatoyoshi pages 1-5)

2.4 Gastrointestinal pathophysiology: inflammatory enteropathy with malabsorption The 2020 GI systematic review (67 total SS cases; 39 with GI involvement) reports high rates of malabsorption testing abnormalities: D-xylose positive in 10/12 and flattened oral glucose tolerance testing in 9/13, interpreted as carbohydrate malabsorption. (pozo2020gastrointestinalmanifestationsin pages 1-2) Clinically, chronic diarrhea predominated (92.3% of GI cases), and severe diarrhea could be fatal; importantly, diarrhea improved with corticosteroid-containing regimens in 6/10 patients where outcomes were described, supporting inflammatory/immune-mediated mechanisms. (pozo2020gastrointestinalmanifestationsin pages 1-2, pozo2020gastrointestinalmanifestationsin pages 2-4)

2.5 Emerging/expanded mechanism: fibrogenesis as a contributor (2024) A 2024 pediatric report describes the first intestinal strictures in SS, with pathology showing patchy fibrosis with crypt/glandular dilatation and clinical dependence on corticosteroids plus repeated endoscopic dilatations; the authors conclude that “in addition to suspected autoimmune pathogenesis, disorders of fibrogenesis may need to be considered.” (pohoreski2024a178gastrointestinalstrictures pages 1-1) This suggests that chronic inflammation may, in some patients, transition to tissue remodeling/fibrosis in the GI tract.

2.6 Ocular inflammation as systemic extension (2023) A 2023 peer-reviewed case report describes granulomatous pan-uveitis and impending central retinal vein occlusion (CRVO) in a patient with SS; the authors state that no prior reports of uveitis/CRVO in SS existed and emphasize systemic corticosteroid/immunosuppressive responsiveness as supporting autoimmune origin. (saima2023impendingcentralretinal pages 4-5)

Key molecular players (genes/proteins), cell types, anatomical locations, and chemical entities

3.1 Genes/proteins (HGNC-level candidates supported by reported autoantibodies) Evidence supports immune recognition of several protein antigens, though not necessarily causal: • GAD (autoantibodies to glutamic acid decarboxylase) reported in a minority of cases. (montanaro2022autoimmunityinsatoyoshi pages 1-5) • Acetylcholine receptor (AChR) autoantibodies reported in a subset of cases. (montanaro2022autoimmunityinsatoyoshi pages 1-5) • Nuclear antigens: ANA positivity is common; 2024 pediatric case shows ENA positivity including anti-Sm and anti-RNP-A, supporting systemic autoimmune activation. (montanaro2022autoimmunityinsatoyoshi pages 8-11, pohoreski2024a178gastrointestinalstrictures pages 1-1) • Unidentified ~90 kDa antigen present in brain/stomach/duodenum lysates (candidate shared tissue antigen). (matsuura2007satoyoshisyndromehas pages 2-4)

Interpretive limitation: these data implicate immune targets but do not establish a single causative autoantigen or genetic driver. (matsuura2007satoyoshisyndromehas pages 2-4, montanaro2022autoimmunityinsatoyoshi pages 8-11)

3.2 Cell types (Cell Ontology; inferred from histology) • Lymphocytes (CL:0000542) and plasma cells (CL:0000786) are implicated by “lymphocytic” / “lymphoplasmacytic” inflammatory infiltrates in GI mucosa and skin. (pozo2020gastrointestinalmanifestationsin pages 1-2, montanaro2022autoimmunityinsatoyoshi pages 8-11)

3.3 Anatomical locations/tissues (UBERON) Key involved tissues include: • Skeletal muscle (UBERON:0001134): painful spasms, sometimes muscle biopsy inflammatory infiltrates in reported cases. (montanaro2022autoimmunityinsatoyoshi pages 5-8) • Hair follicle / skin (hair loss with inflammatory pattern indistinguishable from alopecia areata in some biopsies). (montanaro2022autoimmunityinsatoyoshi pages 5-8, montanaro2022autoimmunityinsatoyoshi pages 8-11) • Gastrointestinal tract mucosa (UBERON:0001555 for digestive tract; specific sites vary): inflammatory infiltrates, malabsorption physiology, diarrhea. (pozo2020gastrointestinalmanifestationsin pages 1-2, matsuura2007satoyoshisyndromehas pages 2-4) • Eye/uvea/retina: granulomatous pan-uveitis and CRVO reported as a complication in 2023. (saima2023impendingcentralretinal pages 1-2) • Bone/growth plates: skeletal abnormalities and growth retardation are frequent (reported in systematic summaries). (montanaro2022autoimmunityinsatoyoshi pages 1-5, pozo2020gastrointestinalmanifestationsin pages 1-2)

3.4 Chemical entities / interventions (CHEBI-oriented; treatment-relevant) Real-world therapies reflect an immune-mediated working model: • Systemic corticosteroids (e.g., prednisolone): widely used; high response proportion in case compilations; steroid responsiveness is repeatedly highlighted. (pozo2019treatmentofsatoyoshi pages 1-2, pozo2019treatmentofsatoyoshi pages 2-4) • Immunosuppressants: tacrolimus, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, cyclophosphamide used as steroid-sparing or adjuncts. (pozo2019treatmentofsatoyoshi pages 1-2, matsuura2007satoyoshisyndromehas pages 1-2) • IV immunoglobulin (IVIG): used in some cases with favorable responses reported in a subset. (pozo2019treatmentofsatoyoshi pages 1-2) • Symptomatic muscle agents: dantrolene improves spasms but not systemic features; anticonvulsants variably helpful. (pozo2019treatmentofsatoyoshi pages 1-2, pozo2019treatmentofsatoyoshi pages 2-4) • 2024 case: upadacitinib (JAK inhibitor) added for alopecia management. (pohoreski2024a178gastrointestinalstrictures pages 1-1) • 2023 ocular case: aspirin and kallidinogenase used for CRVO management alongside immunomodulation. (saima2023impendingcentralretinal pages 2-4)

Biological processes disrupted (GO-oriented suggestions) Because no single pathway is proven, the most evidence-aligned GO terms are those describing immune activation and tissue inflammation/fibrosis: • Immune system process (GO:0002376) and regulation of immune response (GO:0050776) — supported by broad autoantibody positivity and multisystem immune manifestations. (montanaro2022autoimmunityinsatoyoshi pages 8-11) • Adaptive immune response (GO:0002250) / B cell mediated immunity (GO:0019724) — supported by autoantibodies and plasma cell-rich infiltrates. (montanaro2022autoimmunityinsatoyoshi pages 8-11, pozo2020gastrointestinalmanifestationsin pages 1-2) • Inflammatory response (GO:0006954) — supported by GI mucosal inflammatory infiltrates and systemic inflammatory complications. (pozo2020gastrointestinalmanifestationsin pages 1-2, saima2023impendingcentralretinal pages 4-5) • Regulation of smooth/skeletal muscle contraction (e.g., GO:0006937 muscle contraction; GO terms specific to motor neuron regulation are not directly evidenced) — supported indirectly by the hallmark spasms and electrophysiologic “alpha motor neuron” dysregulation statements. (montanaro2022autoimmunityinsatoyoshi pages 5-8) • Fibroblast activation / extracellular matrix organization (GO:0030198) / tissue fibrosis (process-level concept) — supported by 2024 stricture case pathology showing patchy fibrosis and hypothesis of altered fibrogenesis. (pohoreski2024a178gastrointestinalstrictures pages 1-1)
Cellular components (where processes occur) • Extracellular space / circulating compartment: autoantibodies measurable in serum; Western blot reactivity indicates circulating Ig binding tissue lysates. (matsuura2007satoyoshisyndromehas pages 2-4) • Gastrointestinal mucosa (tissue compartment): inflammatory infiltrates within mucosal layers. (matsuura2007satoyoshisyndromehas pages 1-2, pozo2020gastrointestinalmanifestationsin pages 1-2) • Hair follicle microenvironment/skin: inflammatory infiltrates described as similar to alopecia areata in some cases. (montanaro2022autoimmunityinsatoyoshi pages 5-8)
Disease progression model (sequence of events)

6.1 Typical timing Across systematic reviews, onset is commonly in childhood/adolescence (median onset around early teens), with diagnostic delay. (pozo2019treatmentofsatoyoshi pages 2-4, pozo2020gastrointestinalmanifestationsin pages 1-2)

6.2 Proposed stepwise progression (evidence-aligned) Stage 1: Immune tolerance breakdown with emergence of systemic autoimmunity markers (ANA and other autoantibodies) in many patients. (montanaro2022autoimmunityinsatoyoshi pages 8-11) Stage 2: Early target-organ dysfunction: painful spasms (neuromuscular hyperexcitability) and alopecia are usually universal features. (pozo2019treatmentofsatoyoshi pages 2-4) Stage 3: Development of inflammatory enteropathy and malabsorption (D-xylose and OGTT abnormalities) with chronic diarrhea and nutritional consequences (anemia, growth failure). (pozo2020gastrointestinalmanifestationsin pages 1-2, pozo2020gastrointestinalmanifestationsin pages 2-4) Stage 4: Long-term complications: skeletal deformities and endocrine disturbances are frequent in compiled cases; rare organ complications can occur, including ocular inflammatory disease (uveitis/CRVO, 2023). (montanaro2022autoimmunityinsatoyoshi pages 1-5, saima2023impendingcentralretinal pages 4-5) Stage 5 (subset): Chronic inflammation may progress to remodeling/fibrosis, suggested by strictures with patchy fibrosis reported in 2024. (pohoreski2024a178gastrointestinalstrictures pages 1-1)

Phenotypic manifestations (HP-oriented mapping) and mechanistic links

Key phenotypes • Painful muscle spasms/cramps (HP:0003394 “Muscle cramps” as a proxy): universal hallmark and the main morbidity driver; likely reflects neuromuscular hyperexcitability possibly influenced by immune mechanisms. (pozo2019treatmentofsatoyoshi pages 2-4, montanaro2022autoimmunityinsatoyoshi pages 5-8) • Alopecia universalis/totalis (HP:0007418/HP:0002236 depending on ontology mapping): universal in case series; skin histology in some cases resembles alopecia areata, supporting immune attack on hair follicles. (montanaro2022autoimmunityinsatoyoshi pages 8-11) • Chronic diarrhea (HP:0002014) and malabsorption (HP:0002024): predominant GI phenotype with abnormal D-xylose/OGTT and inflammatory infiltrates, consistent with immune-mediated enteropathy. (pozo2020gastrointestinalmanifestationsin pages 1-2) • Growth retardation/short stature (HP:0001510/HP:0004322): common in pediatric cases with severe GI disease, plausibly secondary to malabsorption and chronic inflammation. (pozo2020gastrointestinalmanifestationsin pages 1-2) • Skeletal abnormalities/deformities (broad HP): frequent (e.g., 34% in one systematic compilation). (pozo2019treatmentofsatoyoshi pages 2-4) • Ocular inflammation (uveitis) and retinal vascular complication (CRVO): newly reported manifestation supporting systemic inflammatory disease activity. (saima2023impendingcentralretinal pages 4-5) • GI strictures (new in 2024) with fibrosis: suggests potential chronic inflammatory remodeling. (pohoreski2024a178gastrointestinalstrictures pages 1-1)

Recent developments and latest research (2023–2024 prioritized)

8.1 2023: Ocular inflammatory complication expanding the organ spectrum A 2023 Medicine case report describes granulomatous pan-uveitis with impending CRVO in SS and explicitly frames autoimmune origin based on immunotherapy responsiveness and known autoantibody associations; it recommends clinicians consider uveitis as a complication. (saima2023impendingcentralretinal pages 4-5)

8.2 2024: GI strictures and fibrosis; trial of targeted immunomodulation for alopecia A 2024 pediatric GI abstract reports the first intestinal strictures in SS, with histologic patchy fibrosis and ENA positivity (anti-Sm/anti-RNP), steroid dependence, and repeated endoscopic dilatations; upadacitinib was added for alopecia management, indicating adoption of newer immunomodulatory strategies in practice even in ultra-rare diseases when mechanistically justified. (pohoreski2024a178gastrointestinalstrictures pages 1-1)

Current applications and real-world implementations

9.1 Diagnosis in practice Current practice remains primarily clinical (triad-based) supported by targeted testing: • Serology: ANA and broader autoantibody panels; ENA may be informative in some cases. (montanaro2022autoimmunityinsatoyoshi pages 8-11, pohoreski2024a178gastrointestinalstrictures pages 1-1) • GI work-up: malabsorption testing (D-xylose; OGTT), endoscopy and biopsy demonstrating inflammatory infiltrates; the GI systematic review provides frequency and typical findings. (pozo2020gastrointestinalmanifestationsin pages 1-2, pozo2020gastrointestinalmanifestationsin media c2682e6c) • Research/experimental diagnostics: Western blot evidence of disease-associated bands using brain/GI lysates suggests a potential future biomarker, but the antigen is unknown and this is not a standardized clinical test. (matsuura2007satoyoshisyndromehas pages 2-4)

9.2 Treatment implementation and outcomes Evidence from case compilations indicates the most consistent multi-system improvement is with systemic immunosuppression: • Corticosteroids: response in 28/30 treated cases in one systematic review; among those treated with corticosteroids, deaths were not observed in that subset in the compiled dataset (noting publication bias). (pozo2019treatmentofsatoyoshi pages 1-2, pozo2019treatmentofsatoyoshi pages 2-4) • Steroid-sparing immunosuppressants: tacrolimus and methotrexate are used in practice; tacrolimus is cited as effective in some reports. (matsuura2007satoyoshisyndromehas pages 1-2, saima2023impendingcentralretinal pages 2-4) • Symptomatic neuromuscular therapy: dantrolene improves muscle symptoms in 13/15 but not other manifestations, supporting that spasms can be partially managed independently of systemic autoimmunity. (pozo2019treatmentofsatoyoshi pages 1-2) • Severe GI complications (2024): serial endoscopic dilatation for strictures plus ongoing corticosteroids. (pohoreski2024a178gastrointestinalstrictures pages 1-1) • Ocular complication (2023): escalation of systemic steroids and immunosuppression for uveitis; glaucoma surgery needed for corticosteroid/uveitis-associated pressure complications. (saima2023impendingcentralretinal pages 1-2)

Relevant statistics (from compiled studies)

10.1 Demographics and frequency (systematic reviews) • 2019 treatment systematic review: 64 cases; 73% female; 43% Japanese; median age at diagnosis 16; median symptom onset 11; average diagnostic delay 7.5 years; alopecia and spasms in 100%; alopecia universalis in 63%; digestive symptoms in 58%; skeletal alterations in 34%. (pozo2019treatmentofsatoyoshi pages 2-4) • 2020 GI systematic review: 67 cases identified; 39 (≈58%) had GI manifestations; among GI cases diarrhea occurred in 92.3%; D-xylose positive 10/12; flattened OGTT 9/13; diarrhea improved with corticosteroid-containing regimens in 6/10 with outcome data; severe diarrhea caused death in 3. (pozo2020gastrointestinalmanifestationsin pages 1-2, pozo2020gastrointestinalmanifestationsin pages 2-4) • 2022 autoimmunity systematic review (preprint): 77 cases; 59 female; among 39 tested, 27 (69.2%) had ≥1 autoantibody; ANA most frequent (21); mortality reported ≈10%. (montanaro2022autoimmunityinsatoyoshi pages 8-11)

10.2 Autoantibody prevalence and spectrum In the 2022 autoimmunity review, ANA were the most frequent autoantibodies, with additional reported anti-AChR, anti-DNA, antithyroid, anti-GAD, and antigliadin antibodies. (montanaro2022autoimmunityinsatoyoshi pages 1-5)

Evidence items with PMIDs (note on limitations) The provided tool outputs did not include PubMed IDs (PMIDs), and they are not reliably inferable from DOI alone without external lookup. Accordingly, the report cites DOI/URL and publication venue/date as provided in retrieved sources and flags this as a limitation of the accessible evidence in this run.

Key evidence items (with DOI/URL and dates as provided) • Matsuura et al., “Satoyoshi syndrome has antibody against brain and gastrointestinal tissue.” Muscle & Nerve. Sep 2007. https://doi.org/10.1002/mus.20773 (matsuura2007satoyoshisyndromehas pages 2-4) • del Pozo et al., “Treatment of Satoyoshi syndrome: a systematic review.” Orphanet J Rare Dis. Jun 2019. https://doi.org/10.1186/s13023-019-1120-7 (pozo2019treatmentofsatoyoshi pages 1-2) • del Pozo et al., “Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review.” Orphanet J Rare Dis. May 2020. https://doi.org/10.1186/s13023-020-01395-8 (pozo2020gastrointestinalmanifestationsin pages 1-2) • Montanaro et al., “Autoimmunity in Satoyoshi Disease: a Systematic Review.” MedRxiv preprint. Jul 2022. https://doi.org/10.1101/2022.07.05.22277272 (montanaro2022autoimmunityinsatoyoshi pages 1-5) • Saima et al., “Impending central retinal vein occlusion and granulomatous uveitis in a patient with Satoyoshi syndrome.” Medicine. Mar 2023. https://doi.org/10.1097/MD.0000000000033284 (saima2023impendingcentralretinal pages 1-2) • Pohoreski et al., “A178 Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome.” J Can Assoc Gastroenterol. Feb 2024. https://doi.org/10.1093/jcag/gwad061.178 (pohoreski2024a178gastrointestinalstrictures pages 1-1)

Knowledge-base oriented annotation summary (ready-to-curate)

12.1 Candidate gene/protein annotations (HGNC) • GAD* (glutamic acid decarboxylase; anti-GAD antibodies reported): Immune response against neuronal enzyme; evidence is serologic association in a minority of cases. (montanaro2022autoimmunityinsatoyoshi pages 1-5) • CHRNA1/CHRNB1/CHRND/CHRNE (AChR subunits; anti-AChR antibodies reported): suggests possible neuromuscular junction autoimmunity overlap in some patients. (montanaro2022autoimmunityinsatoyoshi pages 1-5) • Unknown 90 kDa antigen expressed in brain/stomach/duodenum: candidate shared autoantigen. (matsuura2007satoyoshisyndromehas pages 2-4) • Nuclear ribonucleoprotein complex antigens (Sm/RNP; anti-Sm/anti-RNP in 2024 stricture case): systemic autoimmunity signature. (pohoreski2024a178gastrointestinalstrictures pages 1-1)

12.2 GO terms (suggested) • GO:0002376 immune system process (montanaro2022autoimmunityinsatoyoshi pages 8-11) • GO:0006954 inflammatory response (pozo2020gastrointestinalmanifestationsin pages 1-2) • GO:0019724 B cell mediated immunity (montanaro2022autoimmunityinsatoyoshi pages 8-11) • GO:0030198 extracellular matrix organization / fibrosis-related processes (pohoreski2024a178gastrointestinalstrictures pages 1-1)

12.3 HP terms (suggested) • Muscle cramps (HP:0003394) (pozo2019treatmentofsatoyoshi pages 2-4) • Alopecia universalis/totalis (hair loss phenotype) (pozo2019treatmentofsatoyoshi pages 2-4) • Chronic diarrhea (HP:0002014) and malabsorption (HP:0002024) (pozo2020gastrointestinalmanifestationsin pages 1-2) • Growth retardation/short stature (pozo2020gastrointestinalmanifestationsin pages 1-2) • Uveitis (newly reported complication) (saima2023impendingcentralretinal pages 4-5) • Intestinal stricture (newly reported complication) (pohoreski2024a178gastrointestinalstrictures pages 1-1)

12.4 CL terms (suggested) • Lymphocyte (CL:0000542) / plasma cell (CL:0000786) (pozo2020gastrointestinalmanifestationsin pages 1-2)

12.5 UBERON tissues • Skeletal muscle (pozo2019treatmentofsatoyoshi pages 2-4) • GI mucosa/digestive tract (pozo2020gastrointestinalmanifestationsin pages 1-2) • Skin/hair follicle (montanaro2022autoimmunityinsatoyoshi pages 8-11) • Eye/uvea/retina (saima2023impendingcentralretinal pages 1-2)

12.6 CHEBI (treatment chemicals; examples) • Corticosteroids (prednisolone) (saima2023impendingcentralretinal pages 1-2) • Tacrolimus (matsuura2007satoyoshisyndromehas pages 1-2) • Methotrexate (saima2023impendingcentralretinal pages 2-4) • Azathioprine (pozo2019treatmentofsatoyoshi pages 1-2) • IVIG (pozo2019treatmentofsatoyoshi pages 1-2) • Dantrolene (pozo2019treatmentofsatoyoshi pages 1-2) • Upadacitinib (pohoreski2024a178gastrointestinalstrictures pages 1-1)

Conclusion Satoyoshi syndrome is best conceptualized (based on available evidence) as a systemic autoimmune disorder with prominent neuromuscular hyperexcitability, autoimmune-pattern alopecia, and inflammatory/malabsorptive enteropathy; its mechanistic hallmark is immune dysregulation with autoantibodies and tissue inflammatory infiltrates, but the definitive autoantigen(s) and genetic drivers remain unknown. Recent 2023–2024 reports broaden the inflammatory spectrum (uveitis/CRVO) and raise the possibility of chronic inflammation–driven fibrotic remodeling (intestinal strictures with fibrosis), while real-world care continues to rely on immunosuppression (particularly corticosteroids) plus organ-specific symptomatic/procedural management. (saima2023impendingcentralretinal pages 4-5, pohoreski2024a178gastrointestinalstrictures pages 1-1, pozo2019treatmentofsatoyoshi pages 1-2, pozo2020gastrointestinalmanifestationsin pages 1-2)

References

(pozo2019treatmentofsatoyoshi pages 2-4): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Treatment of satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, Jun 2019. URL: https://doi.org/10.1186/s13023-019-1120-7, doi:10.1186/s13023-019-1120-7. This article has 15 citations and is from a peer-reviewed journal.
(pozo2019treatmentofsatoyoshi pages 1-2): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Treatment of satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, Jun 2019. URL: https://doi.org/10.1186/s13023-019-1120-7, doi:10.1186/s13023-019-1120-7. This article has 15 citations and is from a peer-reviewed journal.
(pozo2020gastrointestinalmanifestationsin pages 1-2): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Gastrointestinal manifestations in satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, May 2020. URL: https://doi.org/10.1186/s13023-020-01395-8, doi:10.1186/s13023-020-01395-8. This article has 7 citations and is from a peer-reviewed journal.
(montanaro2022autoimmunityinsatoyoshi pages 1-5): Vinícius Viana Abreu Montanaro, Julián Solís-García del Pozo, Thiago Falcão Hora, Beatriz Helena León, Carlos de Cabo, and Javier Solera. Autoimmunity in satoyoshi disease: a systematic review. MedRxiv, Jul 2022. URL: https://doi.org/10.1101/2022.07.05.22277272, doi:10.1101/2022.07.05.22277272. This article has 0 citations.
(montanaro2022autoimmunityinsatoyoshi pages 8-11): Vinícius Viana Abreu Montanaro, Julián Solís-García del Pozo, Thiago Falcão Hora, Beatriz Helena León, Carlos de Cabo, and Javier Solera. Autoimmunity in satoyoshi disease: a systematic review. MedRxiv, Jul 2022. URL: https://doi.org/10.1101/2022.07.05.22277272, doi:10.1101/2022.07.05.22277272. This article has 0 citations.
(matsuura2007satoyoshisyndromehas pages 1-2): Eiji Matsuura, Wataru Matsuyama, Tomoyuki Sameshima, and Kimiyoshi Arimura. Satoyoshi syndrome has antibody against brain and gastrointestinal tissue. Muscle & Nerve, 36:400-403, Sep 2007. URL: https://doi.org/10.1002/mus.20773, doi:10.1002/mus.20773. This article has 27 citations and is from a peer-reviewed journal.
(saima2023impendingcentralretinal pages 4-5): Yoshinari Saima, Yoshiaki Tanaka, Akihiro Kakehashi, and Toshikatsu Kaburaki. Impending central retinal vein occlusion and granulomatous uveitis in a patient with satoyoshi syndrome. Medicine, 102:e33284, Mar 2023. URL: https://doi.org/10.1097/md.0000000000033284, doi:10.1097/md.0000000000033284. This article has 1 citations and is from a peer-reviewed journal.
(matsuura2007satoyoshisyndromehas pages 2-4): Eiji Matsuura, Wataru Matsuyama, Tomoyuki Sameshima, and Kimiyoshi Arimura. Satoyoshi syndrome has antibody against brain and gastrointestinal tissue. Muscle & Nerve, 36:400-403, Sep 2007. URL: https://doi.org/10.1002/mus.20773, doi:10.1002/mus.20773. This article has 27 citations and is from a peer-reviewed journal.
(pozo2020gastrointestinalmanifestationsin media c2682e6c): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Gastrointestinal manifestations in satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, May 2020. URL: https://doi.org/10.1186/s13023-020-01395-8, doi:10.1186/s13023-020-01395-8. This article has 7 citations and is from a peer-reviewed journal.
(pozo2020gastrointestinalmanifestationsin media 8c8b7812): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Gastrointestinal manifestations in satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, May 2020. URL: https://doi.org/10.1186/s13023-020-01395-8, doi:10.1186/s13023-020-01395-8. This article has 7 citations and is from a peer-reviewed journal.
(pozo2020gastrointestinalmanifestationsin media cce4c213): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Gastrointestinal manifestations in satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, May 2020. URL: https://doi.org/10.1186/s13023-020-01395-8, doi:10.1186/s13023-020-01395-8. This article has 7 citations and is from a peer-reviewed journal.
(pozo2020gastrointestinalmanifestationsin media da01f15f): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Gastrointestinal manifestations in satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, May 2020. URL: https://doi.org/10.1186/s13023-020-01395-8, doi:10.1186/s13023-020-01395-8. This article has 7 citations and is from a peer-reviewed journal.
(montanaro2022autoimmunityinsatoyoshi pages 5-8): Vinícius Viana Abreu Montanaro, Julián Solís-García del Pozo, Thiago Falcão Hora, Beatriz Helena León, Carlos de Cabo, and Javier Solera. Autoimmunity in satoyoshi disease: a systematic review. MedRxiv, Jul 2022. URL: https://doi.org/10.1101/2022.07.05.22277272, doi:10.1101/2022.07.05.22277272. This article has 0 citations.
(pozo2020gastrointestinalmanifestationsin pages 2-4): Julián Solís-García del Pozo, Carlos de Cabo, and Javier Solera. Gastrointestinal manifestations in satoyoshi syndrome: a systematic review. Orphanet Journal of Rare Diseases, May 2020. URL: https://doi.org/10.1186/s13023-020-01395-8, doi:10.1186/s13023-020-01395-8. This article has 7 citations and is from a peer-reviewed journal.
(pohoreski2024a178gastrointestinalstrictures pages 1-1): K. Pohoreski, K. Pajunen, M. Brundler, and I. Wrobel. A178 gastrointestinal strictures in a pediatric patient with satoyoshi syndrome. Journal of the Canadian Association of Gastroenterology, 7:140-140, Feb 2024. URL: https://doi.org/10.1093/jcag/gwad061.178, doi:10.1093/jcag/gwad061.178. This article has 0 citations.
(saima2023impendingcentralretinal pages 1-2): Yoshinari Saima, Yoshiaki Tanaka, Akihiro Kakehashi, and Toshikatsu Kaburaki. Impending central retinal vein occlusion and granulomatous uveitis in a patient with satoyoshi syndrome. Medicine, 102:e33284, Mar 2023. URL: https://doi.org/10.1097/md.0000000000033284, doi:10.1097/md.0000000000033284. This article has 1 citations and is from a peer-reviewed journal.
(saima2023impendingcentralretinal pages 2-4): Yoshinari Saima, Yoshiaki Tanaka, Akihiro Kakehashi, and Toshikatsu Kaburaki. Impending central retinal vein occlusion and granulomatous uveitis in a patient with satoyoshi syndrome. Medicine, 102:e33284, Mar 2023. URL: https://doi.org/10.1097/md.0000000000033284, doi:10.1097/md.0000000000033284. This article has 1 citations and is from a peer-reviewed journal.

{ }

Source YAML

click to show

name: Satoyoshi Syndrome
creation_date: "2026-02-23T00:00:00Z"
updated_date: "2026-02-24T19:00:18Z"
category: Autoimmune
synonyms:
- Komuragaeri disease
parents:
- Autoimmune Disease
- Rare Disease
disease_term:
  preferred_term: Satoyoshi syndrome
  term:
    id: MONDO:0010922
    label: Satoyoshi syndrome
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0010922
      label: Satoyoshi syndrome
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease term for this entry.
    notes: >-
      PMID:32429959 reports external cross-references OMIM:600705 and ORPHA:3130.
      The current schema does not yet expose dedicated OMIM/ORPHA mapping slots.
description: >-
  A rare multisystem disorder characterized by progressive painful muscle spasms,
  alopecia (often progressing to alopecia universalis), chronic diarrhea with
  malabsorption, and skeletal abnormalities. Amenorrhea is common in affected
  females. An autoimmune basis is presumed based on the frequent presence of
  autoantibodies, inflammatory tissue infiltrates, and response to immunosuppressive
  therapy. Approximately 73% of reported cases are female, with median onset
  around age 11 and median age at diagnosis of 16 years. Most cases have been
  reported from Japan.
prevalence:
- population: Global
  percentage: Rare
  notes: >-
    Approximately 64-77 cases have been reported worldwide in the published
    literature as of 2022, indicating extreme rarity.
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 77 patients from 57 articles published between 1967 and 2021
      were included; 59 patients were women. The mean age at diagnosis was 21.2
      years. All cases had painful muscular spasms and alopecia.
    explanation: >-
      Systematic review confirms very low global case counts in the published
      literature, supporting classification as a rare disease.
progression:
- phase: Early neuromuscular-dermatologic phase
  age_range: Childhood to young adulthood
  notes: Painful muscle spasms and alopecia are typically initial and universal manifestations.
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases had painful muscular spasms and alopecia.
    explanation: >-
      This indicates a consistent early core phenotype across reported cases.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mean age at diagnosis was 21.2 years.
    explanation: >-
      Average diagnosis in early life supports onset and recognition in childhood
      or young adulthood.
- phase: Multisystem extension phase
  notes: Gastrointestinal, endocrine, growth, and skeletal manifestations accumulate over time.
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequent manifestations included: diarrhoea, malabsorption, growth
      retardation, amenorrhoea and bone deformity.
    explanation: >-
      This supports progression from core neuromuscular-dermatologic features to
      broader multisystem disease.
- phase: Severe untreated course
  notes: Without immunomodulatory treatment, progression can lead to major disability or death.
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical course without treatment may result in serious disability or death.
    explanation: >-
      This directly supports severe progression risk in untreated disease.
definitions:
- name: Literature case definition for Satoyoshi syndrome
  definition_type: CASE_DEFINITION
  description: >-
    Case-level definition synthesized from systematic reviews, centered on the
    characteristic triad with multisystem supportive features and autoimmune
    context.
  scope: Published case reports and case series
  criteria_sets:
  - name: Core clinical triad
    description: Characteristic high-yield symptom cluster for case recognition.
    minimum_required: 2
    core_clinical_characteristics:
    - preferred_term: Intermittent painful muscle spasms
      term:
        id: HP:0011964
        label: Intermittent painful muscle spasms
    - preferred_term: Alopecia
      term:
        id: HP:0001596
        label: Alopecia
    - preferred_term: Chronic diarrhea
      term:
        id: HP:0002028
        label: Chronic diarrhea
  - name: Multisystem supportive manifestations
    description: Frequent associated findings that strengthen diagnostic confidence.
    minimum_required: 1
    inclusion_criteria:
    - preferred_term: Malabsorption
      term:
        id: HP:0002024
        label: Malabsorption
    - preferred_term: Secondary amenorrhea
      term:
        id: HP:0000869
        label: Secondary amenorrhea
    - preferred_term: Abnormality of the skeletal system
      term:
        id: HP:0000924
        label: Abnormality of the skeletal system
    exclusion_criteria:
    - preferred_term: Alternative causes of painful muscle spasms and chronic diarrhea excluded
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its main symptoms are: painful muscle spasms, diarrhea, alopecia and
      skeletal abnormalities.
    explanation: >-
      This supports the core triad-plus-skeletal pattern used for case
      definition.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases had painful muscular spasms and alopecia.
    explanation: >-
      Universal occurrence of spasms and alopecia supports high-weight core
      criteria.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequent manifestations included: diarrhoea, malabsorption, growth
      retardation, amenorrhoea and bone deformity.
    explanation: >-
      This supports inclusion of multisystem supportive criteria.
pathophysiology:
- name: Systemic Autoimmune Activation
  description: >-
    Satoyoshi syndrome shows systemic immune activation with circulating ANA and
    other autoantibodies in a substantial subset of cases.
  cell_types:
  - preferred_term: Lymphocyte
    term:
      id: CL:0000542
      label: lymphocyte
  - preferred_term: Plasma Cell
    term:
      id: CL:0000786
      label: plasma cell
  biological_processes:
  - preferred_term: B Cell Mediated Immunity
    term:
      id: GO:0019724
      label: B cell mediated immunity
  - preferred_term: Adaptive Immune Response
    term:
      id: GO:0002250
      label: adaptive immune response
  downstream:
  - target: Tissue-Reactive Autoantibody Production
    description: Immune activation yields circulating antibodies against self tissue antigens.
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antinuclear antibodies were detected in 8 out of 16 cases. Antibodies to
      stomach or duodenum tissue lysates were also detected by Western blot.
    explanation: >-
      Detection of ANA and additional tissue-reactive antibodies supports systemic
      autoimmunity as an upstream disease event.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoantibody determinations were performed in 39 patients, of which 27 had
      positive results. The most frequently detected autoantibodies were ANAs.
    explanation: >-
      This broader systematic review confirms frequent autoantibody positivity and
      ANA predominance, reinforcing systemic autoimmune activation.
  - reference: PMID:28940615
    reference_title: "Satoyoshi syndrome-A case report from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is a rare multisystem disorder of presumed autoimmune etiology that is
      characterized by alopecia, intermittent painful muscle spasms, diarrhea, and
      antinuclear antibody positivity.
    explanation: >-
      Independent case-report abstract supports autoimmune etiology and ANA
      positivity in Satoyoshi syndrome.
- name: Tissue-Reactive Autoantibody Production
  description: >-
    Western blot studies identified circulating antibodies that react with brain,
    stomach, and duodenal tissue lysates, consistent with a shared tissue-targeted
    autoimmune response.
  downstream:
  - target: Neuromuscular Circuit Dysfunction
    description: Neural tissue-reactive antibodies are consistent with immune-mediated motor pathway dysfunction.
  - target: Gastrointestinal Mucosal Inflammation
    description: Gastrointestinal tissue-reactive antibodies align with mucosal inflammatory injury.
  - target: Hair Follicle Immune Injury
    description: A systemic tissue-reactive autoimmune profile supports immune targeting of hair follicles.
  evidence:
  - reference: PMID:17405137
    reference_title: "Satoyoshi syndrome has antibody against brain and gastrointestinal tissue."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A common antibody against brain, stomach, and duodenal tissue, according to
      Western blot analysis, was detected in the sera of two patients with this
      syndrome. These findings suggest that Satoyoshi syndrome is a systemic
      autoimmune disease involving the nervous, endocrine, and gastrointestinal
      systems.
    explanation: >-
      This report directly demonstrates tissue-reactive antibodies spanning
      nervous and gastrointestinal systems.
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antibodies to stomach or duodenum tissue lysates were also detected by
      Western blot.
    explanation: >-
      Independent systematic-review evidence reproduces gastrointestinal
      tissue-reactive antibody detection.
- name: Neuromuscular Circuit Dysfunction
  description: >-
    Immune-mediated dysfunction of motor circuitry and neuromuscular signaling is
    a plausible proximal mechanism for abnormal muscle activation.
  cell_types:
  - preferred_term: Skeletal Muscle Fiber
    term:
      id: CL:0000187
      label: muscle cell
  biological_processes:
  - preferred_term: Regulation of Muscle Contraction
    term:
      id: GO:0006937
      label: regulation of muscle contraction
  - preferred_term: Neuromuscular Transmission
    term:
      id: GO:0007274
      label: neuromuscular synaptic transmission
  downstream:
  - target: Painful Muscle Spasms
    description: Perturbed neuromuscular signaling produces recurrent painful spasms.
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome is a multisystemic rare disease of unknown etiology,
      although an autoimmune basis is presumed. Its main symptoms are: painful
      muscle spasms, diarrhea, alopecia and skeletal abnormalities.
    explanation: >-
      Systematic review of 64 cases confirms painful muscle spasms as a universal
      feature, with autoimmune basis presumed but specific neuromuscular mechanism
      not yet resolved.
  - reference: PMID:16972238
    reference_title: "Involuntary painful muscle contractions in Satoyoshi syndrome: a surface electromyographic study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings point to hyperactivity or a disinhibition at the alpha motor
      neuron level, originating probably at that level, although a central origin
      cannot be excluded.
    explanation: >-
      Electrophysiologic data support alpha motor neuron hyperexcitability as a
      proximal mechanism for painful involuntary contractions.
  - reference: PMID:16972238
    reference_title: "Involuntary painful muscle contractions in Satoyoshi syndrome: a surface electromyographic study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      During the involuntary contractions, HD-sEMG showed a fourfold increase in
      amplitude compared to maximal voluntary contractions.
    explanation: >-
      Objective EMG amplitude amplification supports abnormal neuromuscular circuit
      excitability as a proximal event.
  - reference: PMID:28215594
    reference_title: "Adult-onset Satoyoshi syndrome in a young male."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Electroneuromyography showed abnormal spontaneous activity.
    explanation: >-
      Additional electrophysiologic evidence supports neuromuscular hyperexcitability
      as a proximal mechanism.
- name: Gastrointestinal Mucosal Inflammation
  description: >-
    Histology shows predominantly lymphoplasmacytic inflammatory infiltrates
    across the digestive tract.
  cell_types:
  - preferred_term: Lymphocyte
    term:
      id: CL:0000542
      label: lymphocyte
  - preferred_term: Plasma Cell
    term:
      id: CL:0000786
      label: plasma cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Intestinal Absorptive Dysfunction
    description: Persistent mucosal inflammation disrupts nutrient and carbohydrate uptake.
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histological data revealed predominantly lymphoplasmacytic inflammatory
      infiltrate that can affect any section of the digestive tract.
    explanation: >-
      Histological evidence confirms inflammatory infiltration of the GI tract
      consistent with autoimmune-mediated enteropathy.
  - reference: PMID:17405137
    reference_title: "Satoyoshi syndrome has antibody against brain and gastrointestinal tissue."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a patient with this syndrome having a unique "mesh-like" mucosal
      change radiographically and white granules endoscopically in the
      gastrointestinal tract.
    explanation: >-
      Independent endoscopic/radiographic mucosal abnormalities further support GI
      tissue pathology in Satoyoshi syndrome.
- name: Intestinal Absorptive Dysfunction
  description: >-
    Carbohydrate malabsorption is demonstrated by abnormal D-xylose and oral
    glucose tolerance testing.
  biological_processes:
  - preferred_term: Intestinal Absorption
    modifier: DECREASED
    term:
      id: GO:0050892
      label: intestinal absorption
  downstream:
  - target: Malabsorption
    description: Objective absorptive impairment manifests clinically as malabsorption.
  - target: Chronic Diarrhea
    description: Impaired intestinal absorption contributes to persistent diarrhea.
  - target: Short Stature
    description: Chronic malabsorptive disease can impair growth.
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chronic diarrhea was the main digestive symptom (92.3%). Other symptoms such
      as abdominal pain (15.4%), nausea (7.7%) and vomiting (7.7%), were less
      frequent. The D-xylose test was positive in 10 out of 12 patients, and 9 out
      of 13 cases showed a flattened oral glucose tolerance test suggesting
      carbohydrate malabsorption.
    explanation: >-
      Clinical testing demonstrates carbohydrate malabsorption and its close
      association with chronic diarrhea.
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chronic diarrhea may be severe and result in malnutrition, anemia, growth
      retardation, cachexia, disability and even death.
    explanation: >-
      This links prolonged gastrointestinal dysfunction to downstream growth
      consequences.
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chronic diarrhea with malabsorption is one of the most disabling symptoms in
      SS.
    explanation: >-
      This conclusion-level statement directly supports clinically significant
      absorptive dysfunction.
- name: Hair Follicle Immune Injury
  description: >-
    Autoimmune targeting of follicular units is a plausible mechanism for the
    characteristic diffuse hair loss phenotype.
  biological_processes:
  - preferred_term: Immune Response
    term:
      id: GO:0006955
      label: immune response
  downstream:
  - target: Alopecia
    description: Follicular immune injury culminates in diffuse hair loss.
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome is a multisystemic rare disease of unknown etiology,
      although an autoimmune basis is presumed. Its main symptoms are: painful
      muscle spasms, diarrhea, alopecia and skeletal abnormalities.
    explanation: >-
      Systematic review confirms alopecia as one of the main symptoms present in
      100% of reported cases.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases had painful muscular spasms and alopecia.
    explanation: >-
      The larger 77-case review confirms alopecia as a universal feature,
      supporting an upstream follicular injury mechanism.
phenotypes:
- name: Painful Muscle Spasms
  category: Musculoskeletal
  frequency: OBLIGATE
  notes: >-
    Progressive, painful intermittent spasms (komuragaeri) especially of limbs and
    trunk; present in 100% of cases
  phenotype_term:
    preferred_term: Intermittent Painful Muscle Spasms
    term:
      id: HP:0011964
      label: Intermittent painful muscle spasms
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome is a multisystemic rare disease of unknown etiology,
      although an autoimmune basis is presumed. Its main symptoms are: painful
      muscle spasms, diarrhea, alopecia and skeletal abnormalities.
    explanation: >-
      Painful muscle spasms are listed as one of the cardinal symptoms in this
      systematic review of 64 cases.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases had painful muscular spasms and alopecia.
    explanation: >-
      Independent 77-case review confirms painful spasms as a universal phenotype.
  - reference: PMID:9804090
    reference_title: "Satoyoshi's syndrome in an adult: a review of the literature of adult onset cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome consists of painful intermittent muscle spasms, alopecia and
      diarrhea.
    explanation: >-
      Adult-onset review independently confirms painful intermittent spasms as a
      core phenotype.
- name: Alopecia
  category: Dermatological
  frequency: OBLIGATE
  notes: Alopecia reported in 100% of cases across systematic reviews
  phenotype_term:
    preferred_term: Alopecia
    term:
      id: HP:0001596
      label: Alopecia
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases had painful muscular spasms and alopecia.
    explanation: >-
      The largest systematic review (77 cases) reports alopecia as universal in
      Satoyoshi syndrome.
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome is a multisystemic rare disease of unknown etiology,
      although an autoimmune basis is presumed. Its main symptoms are: painful
      muscle spasms, diarrhea, alopecia and skeletal abnormalities.
    explanation: >-
      Independent systematic review (64 cases) also identifies alopecia as a core
      syndrome feature.
- name: Alopecia Universalis
  category: Dermatological
  frequency: FREQUENT
  notes: Universalis subtype reported in approximately 63% of cases
  phenotype_term:
    preferred_term: Alopecia Universalis
    term:
      id: HP:0002289
      label: Alopecia universalis
  evidence:
  - reference: PMID:36930111
    reference_title: "Impending central retinal vein occlusion and granulomatous uveitis in a patient with Satoyoshi syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At the age of 7 years, she developed generalized hair loss and painful
      spasms and was diagnosed with Satoyoshi syndrome.
    explanation: >-
      Case report documents generalized hair loss as a presenting feature of
      Satoyoshi syndrome.
  - reference: PMID:28940615
    reference_title: "Satoyoshi syndrome-A case report from India."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report an 11-year-old girl with Satoyoshi syndrome who presented to the
      dermatology department for treatment of alopecia universalis.
    explanation: >-
      Case report directly documents alopecia universalis as a presenting phenotype.
- name: Chronic Diarrhea
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  notes: Present in 92.3% of cases with GI involvement; can be fatal
  phenotype_term:
    preferred_term: Chronic Diarrhea
    term:
      id: HP:0002028
      label: Chronic diarrhea
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chronic diarrhea was the main digestive symptom (92.3%).
    explanation: >-
      Systematic review identifies chronic diarrhea as the predominant GI symptom
      in 92.3% of cases with gastrointestinal manifestations.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequent manifestations included: diarrhoea, malabsorption, growth
      retardation, amenorrhoea and bone deformity.
    explanation: >-
      Broader case synthesis also classifies diarrhoea as a frequent Satoyoshi
      manifestation.
  - reference: PMID:28267828
    reference_title: "Satoyoshi Syndrome with Progressive Orofacial Manifestations: A Case History Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thereafter, she developed chronic diarrhea, amenorrhea, and skeletal
      deformities.
    explanation: >-
      Case history report independently documents chronic diarrhea among multisystem
      Satoyoshi manifestations.
- name: Malabsorption
  category: Gastrointestinal
  frequency: VERY_FREQUENT
  notes: D-xylose and oral glucose tolerance tests demonstrate carbohydrate malabsorption
  phenotype_term:
    preferred_term: Malabsorption
    term:
      id: HP:0002024
      label: Malabsorption
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The D-xylose test was positive in 10 out of 12 patients, and 9 out of 13
      cases showed a flattened oral glucose tolerance test suggesting carbohydrate
      malabsorption.
    explanation: >-
      Objective malabsorption testing demonstrates carbohydrate malabsorption in
      the majority of tested patients.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequent manifestations included: diarrhoea, malabsorption, growth
      retardation, amenorrhoea and bone deformity.
    explanation: >-
      Independent systematic review evidence confirms malabsorption as a frequent
      manifestation.
- name: Amenorrhea
  category: Endocrine
  frequency: VERY_FREQUENT
  notes: Secondary amenorrhea in affected females
  phenotype_term:
    preferred_term: Secondary Amenorrhea
    term:
      id: HP:0000869
      label: Secondary amenorrhea
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequent manifestations included: diarrhoea, malabsorption, growth
      retardation, amenorrhoea and bone deformity.
    explanation: >-
      Systematic review of 77 cases identifies amenorrhoea as one of the frequent
      manifestations of Satoyoshi syndrome.
  - reference: PMID:15069249
    reference_title: "Satoyoshi syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome (Komuragaeri disease) is a rare disorder of presumed
      autoimmune etiology, characterized by painful muscle spasms, alopecia,
      diarrhea, endocrinopathy with amenorrhoea and secondary skeletal
      abnormalities.
    explanation: >-
      Independent case report abstract explicitly includes amenorrhoea in the
      characteristic syndrome phenotype.
  - reference: PMID:28267828
    reference_title: "Satoyoshi Syndrome with Progressive Orofacial Manifestations: A Case History Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thereafter, she developed chronic diarrhea, amenorrhea, and skeletal
      deformities.
    explanation: >-
      Additional case evidence directly supports amenorrhea in Satoyoshi syndrome.
- name: Short Stature
  category: Growth
  frequency: FREQUENT
  notes: Common in pediatric cases, plausibly secondary to malabsorption and chronic inflammation
  phenotype_term:
    preferred_term: Short Stature
    term:
      id: HP:0004322
      label: Short stature
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Chronic diarrhea may be severe and result in malnutrition, anemia, growth
      retardation, cachexia, disability and even death.
    explanation: >-
      Growth retardation is listed as a consequence of severe chronic diarrhea and
      malabsorption in Satoyoshi syndrome.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequent manifestations included: diarrhoea, malabsorption, growth
      retardation, amenorrhoea and bone deformity.
    explanation: >-
      Systematic review independently confirms growth retardation as a frequent
      manifestation.
- name: Skeletal Abnormalities
  category: Skeletal
  frequency: FREQUENT
  notes: Skeletal alterations reported in approximately 34% of cases
  phenotype_term:
    preferred_term: Abnormality of the skeletal system
    term:
      id: HP:0000924
      label: Abnormality of the skeletal system
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its main symptoms are: painful muscle spasms, diarrhea, alopecia and
      skeletal abnormalities.
    explanation: >-
      Skeletal abnormalities are listed as one of the main symptoms in this
      systematic review of 64 cases.
  - reference: PMID:15069249
    reference_title: "Satoyoshi syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome (Komuragaeri disease) is a rare disorder of presumed
      autoimmune etiology, characterized by painful muscle spasms, alopecia,
      diarrhea, endocrinopathy with amenorrhoea and secondary skeletal
      abnormalities.
    explanation: >-
      Independent case literature explicitly reports secondary skeletal
      abnormalities as part of the syndrome.
  - reference: PMID:28267828
    reference_title: "Satoyoshi Syndrome with Progressive Orofacial Manifestations: A Case History Report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thereafter, she developed chronic diarrhea, amenorrhea, and skeletal
      deformities.
    explanation: >-
      Independent case evidence supports skeletal deformities as part of the
      phenotype spectrum.
  - reference: PMID:12039433
    reference_title: "A unilateral presentation of 'Satoyoshi syndrome'."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The syndrome consists of the following clinical features: (1) painful,
      intermittent muscle spasms; (2) alopecia; (3) diarrhea; and (4) skeletal
      abnormalities in cases of juvenile onset.
    explanation: >-
      This report explicitly lists skeletal abnormalities as a recognized feature
      in juvenile-onset Satoyoshi syndrome.
- name: Uveitis
  category: Ophthalmologic
  frequency: VERY_RARE
  notes: Newly reported complication (2023); granulomatous pan-uveitis with impending CRVO
  phenotype_term:
    preferred_term: Uveitis
    term:
      id: HP:0000554
      label: Uveitis
  evidence:
  - reference: PMID:36930111
    reference_title: "Impending central retinal vein occlusion and granulomatous uveitis in a patient with Satoyoshi syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Unilateral granulomatous pan-uveitis and impending CRVO were observed in
      this patient. Several cases of Satoyoshi syndrome complicated by various
      autoimmune or immunological disorders have been reported. However, to the
      best of our knowledge, no reports of Satoyoshi syndrome presenting with
      uveitis or CRVO have been published. Physicians should consider uveitis as
      a complication of Satoyoshi syndrome.
    explanation: >-
      First reported case of uveitis in Satoyoshi syndrome, expanding the known
      organ spectrum of the disease and supporting systemic autoimmune pathogenesis.
- name: Abdominal Pain
  category: Gastrointestinal
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Abdominal Pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other symptoms such as abdominal pain (15.4%), nausea (7.7%) and vomiting
      (7.7%), were less frequent.
    explanation: >-
      Abdominal pain reported in 15.4% of cases with gastrointestinal involvement.
histopathology:
- name: Gastrointestinal lymphoplasmacytic inflammatory infiltrate
  description: >-
    Digestive tract histology shows predominantly lymphoplasmacytic inflammatory
    infiltrates, consistent with inflammatory enteropathy.
  frequency: FREQUENT
  diagnostic: false
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histological data revealed predominantly lymphoplasmacytic inflammatory
      infiltrate that can affect any section of the digestive tract.
    explanation: >-
      This directly supports a characteristic microscopic inflammatory finding in
      Satoyoshi syndrome gastrointestinal disease.
- name: Gastrointestinal mucosal structural abnormalities
  description: >-
    Reported gastrointestinal pathology includes diffuse mucosal structural
    abnormalities seen on radiographic and endoscopic assessment.
  frequency: OCCASIONAL
  diagnostic: false
  evidence:
  - reference: PMID:17405137
    reference_title: "Satoyoshi syndrome has antibody against brain and gastrointestinal tissue."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We present a patient with this syndrome having a unique "mesh-like" mucosal
      change radiographically and white granules endoscopically in the
      gastrointestinal tract.
    explanation: >-
      This supports additional gastrointestinal tissue-level pathology beyond the
      inflammatory infiltrate pattern.
biochemical:
- name: Antinuclear Antibodies (ANA)
  presence: Variable
  context: Most commonly detected autoantibody; found in 8/16 GI-series cases and 21/39 in autoimmunity review
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antinuclear antibodies were detected in 8 out of 16 cases.
    explanation: >-
      ANA are the most frequently detected autoantibody in Satoyoshi syndrome
      patients.
- name: Anti-Brain and GI Tissue Antibodies
  presence: Positive
  context: Circulating antibodies targeting a ~90 kDa antigen in brain, stomach, and duodenal lysates
  evidence:
  - reference: PMID:17405137
    reference_title: "Satoyoshi syndrome has antibody against brain and gastrointestinal tissue."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A common antibody against brain, stomach, and duodenal tissue, according to
      Western blot analysis, was detected in the sera of two patients with this
      syndrome.
    explanation: >-
      Western blot demonstrates a shared tissue-reactive autoantibody in Satoyoshi
      syndrome sera, supporting a common autoantigen across nervous and
      gastrointestinal systems.
genetic:
- name: No established monogenic etiology
  association: Unknown
  notes: >-
    No single causative gene has been confirmed; current evidence supports a
    probable autoimmune disorder with unresolved molecular etiology.
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Satoyoshi syndrome is a multisystemic rare disease of unknown etiology,
      although an autoimmune basis is presumed.
    explanation: >-
      This review explicitly states that disease etiology remains unknown.
  - reference: PMID:16972238
    reference_title: "Involuntary painful muscle contractions in Satoyoshi syndrome: a surface electromyographic study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although an autoimmune origin of Satoyoshi syndrome seems likely, its exact
      etiology remains as yet unknown, as is the origin of the involuntary
      contractions.
    explanation: >-
      Electrophysiology-focused case study confirms unresolved etiology despite
      autoimmune evidence.
environmental: []
treatments:
- name: Corticosteroids
  description: >-
    First-line treatment with the best overall results. 28 out of 30 cases responded
    to a regimen that included corticosteroids. Corticosteroid-containing regimens
    improved diarrhea in 6 out of 10 patients with GI involvement. None of the
    three patients who died had received corticosteroids or immunosuppressants.
  treatment_term:
    preferred_term: corticosteroid agent therapy
    term:
      id: MAXO:0000640
      label: corticosteroid agent therapy
    qualifiers:
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: prednisone
        term:
          id: CHEBI:8382
          label: prednisone
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: prednisolone
        term:
          id: CHEBI:8378
          label: prednisolone
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      28 out of 30 cases responded to a regimen that included costicosteroids.
    explanation: >-
      Systematic review demonstrates that corticosteroid-containing regimens
      produced favorable responses in the large majority of treated cases.
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In 6 out of 10 patients, diarrhea improved with a treatment regimen that
      included corticosteroids.
    explanation: >-
      Corticosteroid-containing regimens specifically improved gastrointestinal
      symptoms, supporting the inflammatory/autoimmune basis of the enteropathy.
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      None of the three patients who died had received corticosteroids or
      immunosuppressants.
    explanation: >-
      The observation that all fatal cases lacked immunosuppressive treatment
      suggests corticosteroids may reduce mortality, though publication bias
      must be considered.
- name: Dantrolene
  description: >-
    Muscle relaxant that improved muscle symptoms in 13 out of 15 cases, but did
    not improve any other symptoms of the disease. Used for symptomatic management
    of painful spasms.
  treatment_term:
    preferred_term: skeletal muscle relaxant agent therapy
    term:
      id: MAXO:0000324
      label: skeletal muscle relaxant agent therapy
    qualifiers:
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: dantrolene
        term:
          id: CHEBI:4317
          label: dantrolene
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Dantrolene improved muscle symptoms in 13 out of 15 cases, but not any other
      symptoms of the disease.
    explanation: >-
      Dantrolene is effective for muscle spasm control but does not address the
      underlying autoimmune process or other systemic manifestations.
- name: Immunosuppressive Agents
  description: >-
    Various immunosuppressants including cyclosporine, mycophenolate mofetil,
    azathioprine, methotrexate, tacrolimus, and cyclophosphamide have been used
    as steroid-sparing agents or to improve efficacy of treatment.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: cyclosporine
        term:
          id: CHEBI:4031
          label: cyclosporin A
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: mycophenolate mofetil
        term:
          id: CHEBI:8764
          label: mycophenolate mofetil
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: azathioprine
        term:
          id: CHEBI:2948
          label: azathioprine
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: methotrexate
        term:
          id: CHEBI:44185
          label: methotrexate
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: tacrolimus
        term:
          id: CHEBI:61049
          label: tacrolimus (anhydrous)
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: cyclophosphamide
        term:
          id: CHEBI:4027
          label: cyclophosphamide
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Other immunosuppressive drugs including cyclosporine, mycophenolate mofetil,
      azathioprine, methotrexate, tacrolimus and cyclophosphamide were used to
      decrease corticosteroid dose or improve efficacy.
    explanation: >-
      Multiple immunosuppressive agents have been employed as steroid-sparing
      therapy in Satoyoshi syndrome.
- name: Intravenous Immunoglobulin (IVIG)
  description: >-
    Used in some cases with variable response. Four out of nine patients treated
    with IVIG obtained a favorable response.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: pharmacologic substance
        term:
          id: NCIT:C1909
          label: Pharmacologic Substance
      value:
        preferred_term: human immunoglobulin G
        term:
          id: NCIT:C80829
          label: Human Immunoglobulin G
  evidence:
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Immunoglobulin therapy was used in nine patients and four of them obtained a
      favorable response.
    explanation: >-
      IVIG produced favorable responses in less than half of treated patients,
      indicating variable efficacy.
epidemiology:
- name: Female proportion among published cases (1967-2021)
  description: Female share in the pooled published-case cohort.
  unit: percentage
  mean_range: "76.6"
  notes: Derived from 59/77 female cases in the 2023 systematic review cohort.
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A total of 77 patients from 57 articles published between 1967 and 2021
      were included; 59 patients were women.
    explanation: >-
      This supports female predominance among reported Satoyoshi syndrome cases.
- name: Gastrointestinal manifestations among reported Satoyoshi cases (through 2019)
  description: Proportion of reported Satoyoshi cases with gastrointestinal manifestations.
  unit: percentage
  mean_range: "58.2"
  notes: Derived from 39/67 reported cases with GI manifestations.
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sixty-seven cases of SS were found up until December 2019. Thirty-nine
      cases described gastrointestinal manifestations.
    explanation: >-
      This provides the denominator and numerator for GI-manifestation proportion
      among reported Satoyoshi cases.
- name: Chronic diarrhea among Satoyoshi cases with gastrointestinal manifestations
  description: Proportion of chronic diarrhea within the GI-manifesting Satoyoshi subset.
  unit: percentage
  mean_range: "92.3"
  notes: Proportion within GI-involved Satoyoshi case subset.
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Chronic diarrhea was the main digestive symptom (92.3%).
    explanation: >-
      This gives a percentage-based epidemiologic estimate for chronic diarrhea in
      GI-manifesting Satoyoshi syndrome.
- name: Mean age at diagnosis in published cases
  description: Mean age at diagnosis from systematic review case aggregation.
  unit: years
  mean_range: "21.2"
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The mean age at diagnosis was 21.2 years.
    explanation: >-
      This provides a pooled central estimate of diagnostic age in published
      Satoyoshi syndrome cases.
- name: Autoantibody positivity among tested cases
  description: Fraction of patients with at least one positive autoantibody among those tested.
  unit: proportion
  mean_range: "27/39"
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoantibody determinations were performed in 39 patients, of which 27 had
      positive results.
    explanation: >-
      This quantifies the high serologic autoimmunity burden in reported cases.
diagnosis:
- name: Clinical pattern recognition
  presence: Characteristic multisystem constellation
  description: >-
    Diagnosis is primarily clinical, based on the combination of painful muscle
    spasms and alopecia with frequent gastrointestinal and skeletal/endocrine
    features.
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All cases had painful muscular spasms and alopecia.
    explanation: >-
      Universal co-occurrence of these two manifestations supports their central
      diagnostic importance.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Frequent manifestations included: diarrhoea, malabsorption, growth
      retardation, amenorrhoea and bone deformity.
    explanation: >-
      Frequent multisystem manifestations further define the recognizable clinical
      syndrome.
- name: Autoantibody assessment
  presence: Frequently positive
  markers: ANA and less frequently anti-acetylcholine receptor, anti-DNA, antithyroid, anti-GAD, and antigliadin antibodies
  evidence:
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autoantibody determinations were performed in 39 patients, of which 27 had
      positive results.
    explanation: >-
      High frequency of positive autoantibodies supports routine serologic
      autoimmune evaluation.
  - reference: PMID:36749015
    reference_title: "Is Satoyoshi syndrome an autoimmune disease? A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The most frequently detected autoantibodies were ANAs. Other less frequently
      found autoantibodies were: anti-acetylcholine receptor antibodies, anti-DNA
      antibodies, antithyroid antibodies, anti-glutamic acid decarboxylase
      (anti-GAD) and anti-gliadin antibodies.
    explanation: >-
      This identifies the most informative autoantibody panel components reported
      in the literature.
- name: Gastrointestinal malabsorption testing
  presence: Frequently abnormal in patients with digestive involvement
  results: D-xylose and oral glucose tolerance test abnormalities consistent with carbohydrate malabsorption
  evidence:
  - reference: PMID:32429959
    reference_title: "Gastrointestinal manifestations in Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The D-xylose test was positive in 10 out of 12 patients, and 9 out of 13
      cases showed a flattened oral glucose tolerance test suggesting carbohydrate
      malabsorption.
    explanation: >-
      Objective absorptive testing provides supportive diagnostic evidence for the
      gastrointestinal component.
- name: Surface electromyography during spasms
  presence: Abnormal
  description: >-
    Surface EMG can document high-amplitude involuntary contractions and support
    motor hyperexcitability physiology.
  evidence:
  - reference: PMID:16972238
    reference_title: "Involuntary painful muscle contractions in Satoyoshi syndrome: a surface electromyographic study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      During the involuntary contractions, HD-sEMG showed a fourfold increase in
      amplitude compared to maximal voluntary contractions.
    explanation: >-
      Electrophysiology directly captures abnormal motor activity during painful
      contractions.
- name: Tissue-reactive antibody Western blot (research support)
  presence: Reported positive
  description: Western blot reactivity to brain and gastrointestinal tissue lysates has been reported in Satoyoshi syndrome sera.
  evidence:
  - reference: PMID:17405137
    reference_title: "Satoyoshi syndrome has antibody against brain and gastrointestinal tissue."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A common antibody against brain, stomach, and duodenal tissue, according to
      Western blot analysis, was detected in the sera of two patients with this
      syndrome.
    explanation: >-
      Tissue-reactive antibody detection supports the autoimmune diagnosis model.
differential_diagnoses:
- name: Classic stiff person syndrome
  description: >-
    Both disorders can present with painful muscle spasms, but classic stiff
    person syndrome is defined by prominent persistent body stiffness and
    characteristic axial involvement.
  disease_term:
    preferred_term: classic stiff person syndrome
    term:
      id: MONDO:0018625
      label: classic stiff person syndrome
  distinguishing_features:
  - Typical SPS presentation includes generalized body stiffness and exaggerated lumbar lordosis.
  - Satoyoshi syndrome instead has obligate alopecia and frequent chronic diarrhea/malabsorption.
  evidence:
  - reference: PMID:23186907
    reference_title: "Stiff person syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is uncommon, characterized by body stiffness associated with painful
      muscle spasms, and varies in location and severity.
    explanation: >-
      Confirms the painful spasm overlap and defining stiffness phenotype of SPS.
  - reference: PMID:23186907
    reference_title: "Stiff person syndrome."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Most patients demonstrate exaggerated lumbar lordosis.
    explanation: >-
      Lumbar lordosis is a characteristic SPS feature that helps distinguish it
      from Satoyoshi syndrome.
  - reference: PMID:31217029
    reference_title: "Treatment of Satoyoshi syndrome: a systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Its main symptoms are: painful muscle spasms, diarrhea, alopecia and
      skeletal abnormalities.
    explanation: >-
      Satoyoshi-specific multisystem features (especially alopecia and diarrhea)
      help distinguish it from SPS.
- name: Isaac syndrome
  description: >-
    Both disorders can involve painful cramps/spasms, but Isaac syndrome is a
    peripheral nerve hyperexcitability disorder with continuous motor activity
    and characteristic myokymia/fasciculations.
  disease_term:
    preferred_term: Isaac syndrome
    term:
      id: MONDO:0019399
      label: Isaac syndrome
  distinguishing_features:
  - Continuous motor activity with fasciculations and myokymia suggests Isaac syndrome.
  - Electrodiagnostic after-discharges and neuromyotonic/myokymic discharges are typical for Isaac syndrome.
  evidence:
  - reference: PMID:25736532
    reference_title: "Isaacs syndrome: A review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Isaacs syndrome is a peripheral nerve hyperexcitability (PNH) syndrome that
      presents as continuous motor activity. Clinical findings include cramps,
      fasciculations, and myokymia.
    explanation: >-
      This defines key clinical features that separate Isaac syndrome from the
      broader multisystem Satoyoshi phenotype.
  - reference: PMID:25736532
    reference_title: "Isaacs syndrome: A review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Electrodiagnosis plays a key role in diagnosis by demonstrating
      after-discharges on nerve conduction studies, and fasciculation potentials,
      myokymic discharges, neuromyotonic discharges, and other types of abnormal
      spontaneous activity on needle examination.
    explanation: >-
      Characteristic electrodiagnostic findings provide a key differentiator from
      Satoyoshi syndrome.
animal_models: []
clinical_trials: []
datasets: []